Defining benchmarks for pelvic exenteration surgery: a multicentre analysis of patients with locally advanced and recurrent rectal cancer
Authors
Brown, K. G. M.Solomon, M. J.
Koh, C. E.
Sutton, Paul A
Aguiar, S., Jr.
Bezerra, T. S.
Clouston, H. W.
Desouza, A.
Dozois, E. J.
Ersryd, A. L.
Frizelle, F.
Funder, J. A.
Garcia-Aguilar, J.
Garfinkle, R.
Glyn, T.
Heriot, A.
Kanemitsu, Y.
Kong, C. Y.
Kristensen, H.
Malakorn, S.
Mens, D. M.
Nilsson, P. J.
Palmer, G. J.
Pappou, E.
Quinn, M.
Quyn, A. J.
Sahakitrungruang, C.
Saklani, A.
Solbakken, A. M.
Tiernan, J. P.
Verhoef, C.
Steffens, D.
Affiliation
Colorectal & Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
OBJECTIVE: To establish globally applicable benchmark outcomes for pelvic exenteration (PE) in patients with locally advanced primary (LARC) and recurrent rectal cancer (LRRC), using outcomes achieved at highly specialised centres. BACKGROUND DATA: PE is established as the standard of care for selected patients with LARC and LRRC. There are currently no available benchmarks against which surgical performance in PE can be compared for audit and quality improvement. METHODS: This international multicentre retrospective cohort study included patients undergoing PE for LARC or LRRC at 16 highly experienced centres between 2018 and 2023. Ten outcome benchmarks were established in a lower-risk subgroup. Benchmarks were defined by the 75th percentile of the results achieved at the individual centres. RESULTS: 763 patients underwent PE, of which 464 patients (61%) had LARC and 299 (39%) had LRRC. 544 patients (71%) who met predefined lower risk criteria formed the benchmark cohort. For LARC patients, the calculated benchmark threshold for major complication rate was ≤44%; comprehensive complication index (CCI): ≤30.2; 30-day mortality rate: 0%; 90-day mortality rate: ≤4.3%; R0 resection rate: ≥79%. For LRRC patients, the calculated benchmark threshold for major complication rate was ≤53%; CCI: ≤34.1; 30-day mortality rate: 0%; 90-day mortality rate: ≤6%; R0 resection rate: ≥77%. CONCLUSIONS: The reported benchmarks for PE in patients with LARC and LRRC represent the best available care for this patient group globally and can be used for rigorous assessment of surgical quality and to facilitate quality improvement initiatives at international exenteration centres.Citation
Brown KGM, Solomon MJ, Koh CE, Sutton PA, Aguiar S, Jr., Bezerra TS, et al. Defining Benchmarks for Pelvic Exenteration Surgery: A Multicentre Analysis of Patients with Locally Advanced and Recurrent Rectal Cancer. Ann Surg. 2024 May 15. PubMed PMID: 38747145. Epub 2024/05/15. eng.Journal
Annals of SurgeryDOI
10.1097/sla.0000000000006348PubMed ID
38747145Additional Links
https://dx.doi.org/10.1097/sla.0000000000006348Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1097/sla.0000000000006348
Scopus Count
Collections
Related articles
- Contemporary results from the PelvEx collaborative: improvements in surgical outcomes for locally advanced and recurrent rectal cancer.
- Authors: PelvEx Collaborative
- Issue date: 2024 May
- Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer.
- Authors: PelvEx Collaborative
- Issue date: 2019 Aug
- Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.
- Authors: Gould LE, Pring ET, Moorghen M, Burns EM, Antoniou A, Steele CW, Roxburgh CS, Jenkins JT
- Issue date: 2023 Nov
- Bladder preservation or complete cystectomy during pelvic exenteration of patients with locally advanced or recurrent rectal cancer, what should we do?
- Authors: Palma CA, van Kessel CS, Solomon MJ, Leslie S, Jeffery N, Lee PJ, Austin KKS
- Issue date: 2023 Jul
- A systematic review of oncosurgical and quality of life outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer.
- Authors: Maudsley J, Clifford RE, Aziz O, Sutton PA
- Issue date: 2025 Jan